Ryan G. Kruger

10.1k total citations
53 papers, 2.6k citations indexed

About

Ryan G. Kruger is a scholar working on Molecular Biology, Finance and Pharmacology. According to data from OpenAlex, Ryan G. Kruger has authored 53 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 10 papers in Finance and 7 papers in Pharmacology. Recurrent topics in Ryan G. Kruger's work include Epigenetics and DNA Methylation (14 papers), Cancer-related gene regulation (10 papers) and Biochemical and Structural Characterization (10 papers). Ryan G. Kruger is often cited by papers focused on Epigenetics and DNA Methylation (14 papers), Cancer-related gene regulation (10 papers) and Biochemical and Structural Characterization (10 papers). Ryan G. Kruger collaborates with scholars based in United States, South Africa and United Kingdom. Ryan G. Kruger's co-authors include Dewey G. McCafferty, Brenda A. Frankel, Matthew L. Bentley, Predrag Čudić, Olena Barbash, Helai P. Mohammad, Thomas Walz, Gunn‐Guang Liou, Jason C. Tanny and Danesh Moazed and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Ryan G. Kruger

53 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryan G. Kruger United States 27 2.0k 382 325 291 162 53 2.6k
Huawei Chen United States 32 2.1k 1.0× 395 1.0× 394 1.2× 810 2.8× 32 0.2× 81 2.9k
Joachim Gullbo Sweden 36 2.9k 1.4× 329 0.9× 1.1k 3.4× 155 0.5× 161 1.0× 100 4.0k
Daishiro Ikeda Japan 27 1.1k 0.6× 679 1.8× 273 0.8× 660 2.3× 48 0.3× 120 2.0k
Yong‐Su Zhen China 26 1.5k 0.8× 356 0.9× 658 2.0× 154 0.5× 67 0.4× 154 2.3k
T. Krojer United Kingdom 31 2.3k 1.1× 161 0.4× 270 0.8× 75 0.3× 65 0.4× 57 3.1k
Klaus G. Steube Germany 24 603 0.3× 324 0.8× 243 0.7× 311 1.1× 74 0.5× 53 1.5k
Richard A. Pauptit United Kingdom 25 1.8k 0.9× 526 1.4× 558 1.7× 132 0.5× 102 0.6× 42 2.6k
Kazuo Nitta Japan 27 1.5k 0.8× 242 0.6× 445 1.4× 150 0.5× 76 0.5× 124 2.4k
Joakim E. Swedberg Australia 24 1.0k 0.5× 221 0.6× 196 0.6× 68 0.2× 209 1.3× 44 1.3k
Malika Kumarasiri United States 24 850 0.4× 383 1.0× 370 1.1× 187 0.6× 61 0.4× 34 1.9k

Countries citing papers authored by Ryan G. Kruger

Since Specialization
Citations

This map shows the geographic impact of Ryan G. Kruger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan G. Kruger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan G. Kruger more than expected).

Fields of papers citing papers by Ryan G. Kruger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan G. Kruger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan G. Kruger. The network helps show where Ryan G. Kruger may publish in the future.

Co-authorship network of co-authors of Ryan G. Kruger

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan G. Kruger. A scholar is included among the top collaborators of Ryan G. Kruger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan G. Kruger. Ryan G. Kruger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
O’Brien, Shane W., Christine Thompson, Boris G. Wilson, et al.. (2023). Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer. BMC Cancer. 23(1). 775–775. 16 indexed citations
2.
Fedoriw, Andrew, Leilei Shi, Shane W. O’Brien, et al.. (2022). Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses. Cancer Immunology Research. 10(4). 420–436. 26 indexed citations
3.
Bauer, Todd M., Benjamin Besse, Alex Martínez‐Martí, et al.. (2019). Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC. Journal of Thoracic Oncology. 14(10). 1828–1838. 61 indexed citations
4.
Cusan, Monica, Sheng F. Cai, Helai P. Mohammad, et al.. (2018). LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. Blood. 131(15). 1730–1742. 81 indexed citations
5.
Kellner, Wendy A., Christine Thompson, Melissa B. Pappalardi, et al.. (2018). Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing. Scientific Reports. 8(1). 9711–9711. 121 indexed citations
6.
Wyce, Anastasia, Shawn W. Foley, Satyajit Rajapurkar, et al.. (2018). MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers. Oncogenesis. 7(4). 35–35. 23 indexed citations
7.
Aller, Glenn S. Van, Alan P. Graves, P.A. Elkins, et al.. (2016). Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets. Structure. 24(5). 774–781. 42 indexed citations
8.
Ott, Heidi M., Alan P. Graves, Melissa B. Pappalardi, et al.. (2014). A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation. Molecular Cancer Therapeutics. 13(12). 3062–3073. 35 indexed citations
9.
Kruger, Ryan G., et al.. (2014). The consistency of equity style anomalies on the JSE during a period of market crisis. RePEc: Research Papers in Economics. 16(1). 1–18. 5 indexed citations
10.
Kruger, Ryan G., et al.. (2012). Nonlinear serial dependence in share returns on the Johannesburg Stock Exchange. RePEc: Research Papers in Economics. 14(2). 64–84. 2 indexed citations
11.
Aller, Glenn S. Van, Nicolas Reynoird, Olena Barbash, et al.. (2012). Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics. 7(4). 340–343. 140 indexed citations
12.
Sabbatini, Peter, Susan Korenchuk, Jason L. Rowand, et al.. (2009). GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Molecular Cancer Therapeutics. 8(10). 2811–2820. 86 indexed citations
13.
Gilmartin, Aidan G., Maureen R. Bleam, Mark C. Richter, et al.. (2009). Distinct Concentration-Dependent Effects of the Polo-like Kinase 1–Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis. Cancer Research. 69(17). 6969–6977. 100 indexed citations
14.
Rabindran, Sridhar K., Peter Sabbatini, Susan Korenchuk, et al.. (2009). Abstract #1740: Characterization of GSK1838705A, a small molecule inhibitor of the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase that delays growth of IGF-1R-dependent tumors and causes regression of ALK-dependent tumors in vivo. Cancer Research. 69. 1740–1740. 2 indexed citations
15.
Lü, Wei, Catherine Leimkuhler, Gregory J. Gatto, et al.. (2005). AknT Is an Activating Protein for the Glycosyltransferase AknS in L-Aminodeoxysugar Transfer to the Aglycone of Aclacinomycin A. Chemistry & Biology. 12(5). 527–534. 57 indexed citations
16.
Kruger, Ryan G., Wei Lü, Markus Oberthür, et al.. (2005). Tailoring of Glycopeptide Scaffolds by the Acyltransferases from the Teicoplanin and A-40,926 Biosynthetic Operons. Chemistry & Biology. 12(1). 131–140. 43 indexed citations
17.
Liou, Gunn‐Guang, Jason C. Tanny, Ryan G. Kruger, Thomas Walz, & Danesh Moazed. (2005). Assembly of the SIR Complex and Its Regulation by O-Acetyl-ADP-Ribose, a Product of NAD-Dependent Histone Deacetylation. Cell. 121(4). 515–527. 208 indexed citations
18.
Čudić, Predrag, James K. Kranz, Douglas C. Behenna, et al.. (2002). Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: Minimal structural requirements for intermolecular complexation and fibril formation. Proceedings of the National Academy of Sciences. 99(11). 7384–7389. 58 indexed citations
19.
McCafferty, Dewey G., et al.. (2002). Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers. 66(4). 261–284. 95 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Huawei Chen Breakdown of academic impact, for papers by Joachim Gullbo Breakdown of academic impact, for papers by Daishiro Ikeda Breakdown of academic impact, for papers by Yong‐Su Zhen Breakdown of academic impact, for papers by T. Krojer Breakdown of academic impact, for papers by Klaus G. Steube Breakdown of academic impact, for papers by Richard A. Pauptit Breakdown of academic impact, for papers by Kazuo Nitta Breakdown of academic impact, for papers by Joakim E. Swedberg Breakdown of academic impact, for papers by Malika Kumarasiri
Rankless by CCL
2026